The best of times, the worst of times
Article Abstract:
The biotech industry has become very vibrant and successful in last 30 years, with 120 approved products, 300 in development and around 2,500 companies in existence as demographic trends show that people favor healthcare sector and are ready to pay for a quality life. Public investors are looking for investing in mutual funds and hedge funds for a shorter period of time having good liquidity, which is no doubt profitable but would lead to stock price volatility and instability for biotech companies in long run.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Welcoming biotech with open arms
Article Abstract:
The development of the North Carolina Biotechnology Center as a private, nonprofit organization for future research, development and education in biotechnology encouraged the Tarheel state to invest in their industries. The congenial climate, infrastructure and skilled workforce of the state has led to the development of several biotech related industries, which provides success, as well as federal benefits to the government.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Buyer's market
Article Abstract:
In the present job market, the more experienced candidate may be at a disadvantage as companies look for less experienced workers. There are more job openings for people with 2-10 years experience and acquisition of smaller companies is also beneficial since the employees are very productive, as they opt for financial stability, with the market environment favoring companies in compensation packages.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2006
User Contributions:
Comment about this article or add new information about this topic: